Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Given Average Rating of “Moderate Buy” by Brokerages

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) has been given an average recommendation of “Moderate Buy” by the thirteen analysts that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, eleven have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among analysts that have covered the stock in the last year is $58.1111.

Several research analysts have issued reports on the company. HC Wainwright boosted their target price on Terns Pharmaceuticals from $20.00 to $60.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. Wall Street Zen upgraded Terns Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, February 14th. William Blair raised shares of Terns Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Monday, November 3rd. Truist Financial boosted their price target on shares of Terns Pharmaceuticals from $35.00 to $56.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. Finally, Mizuho lifted their price objective on shares of Terns Pharmaceuticals from $33.00 to $54.00 and gave the company an “outperform” rating in a report on Tuesday, December 9th.

Insiders Place Their Bets

In other news, insider Emil Kuriakose sold 1,155 shares of the company’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $38.57, for a total transaction of $44,548.35. Following the transaction, the insider directly owned 50,365 shares of the company’s stock, valued at approximately $1,942,578.05. This represents a 2.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Amy L. Burroughs sold 71,339 shares of the stock in a transaction on Monday, January 5th. The shares were sold at an average price of $38.10, for a total value of $2,718,015.90. Following the sale, the chief executive officer owned 138,976 shares of the company’s stock, valued at approximately $5,294,985.60. This represents a 33.92% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 155,826 shares of company stock worth $5,882,597. Insiders own 1.50% of the company’s stock.

Institutional Trading of Terns Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. Commodore Capital LP purchased a new stake in shares of Terns Pharmaceuticals during the third quarter worth about $42,807,000. Vestal Point Capital LP acquired a new position in shares of Terns Pharmaceuticals during the 4th quarter worth approximately $181,800,000. Janus Henderson Group PLC acquired a new stake in shares of Terns Pharmaceuticals in the 4th quarter worth $136,496,000. Capitolis Liquid Global Markets LLC acquired a new stake in Terns Pharmaceuticals during the fourth quarter worth about $123,026,000. Finally, Lord Abbett & CO. LLC purchased a new position in shares of Terns Pharmaceuticals during the 4th quarter worth approximately $109,581,000. Institutional investors and hedge funds own 98.26% of the company’s stock.

Terns Pharmaceuticals Price Performance

NASDAQ:TERN opened at $39.35 on Thursday. The stock’s 50 day simple moving average is $38.52 and its two-hundred day simple moving average is $21.95. Terns Pharmaceuticals has a 1 year low of $1.87 and a 1 year high of $48.26. The company has a market cap of $4.08 billion, a price-to-earnings ratio of -38.20 and a beta of -0.28.

Terns Pharmaceuticals Company Profile

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.